Professor Christopher Goldring BSc, PhD

Research Grants

Developing a collaborative resource for ChIP based analyses of cancer related transcriptional networks

CANCER RESEARCH UK (CRUK) (UK)

April 2012 - March 2013

Vacation Scholarship. The role of the Nrf2-keap 1 pathway in regulation of chemoresistance.

WELLCOME TRUST (UK)

July 2008 - August 2008

Regenerative Medicine Platform in Stem Cell Safety Science

MEDICAL RESEARCH COUNCIL (MRC)

June 2013 - March 2018

Definition of the mechanisms that underlie the decrease in expression of the cytochrome P450s in primary hepatocytes.

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

June 2007 - December 2009

Manipulation of the physiological and toxicological phenotype of human hepatocytes by targeting cellular differentiation and de-differentiation

MEDICAL RESEARCH COUNCIL (MRC)

October 2014 - September 2018

Investigation of Inflammatory Signalling during Drug-induced Hepatotoxicity Background

BRITISH TOXICOLOGY SOCIETY (UK)

October 2007 - September 2010

The chemical and molecular basis of the prevention of drug-induced liver injury by Nrf2.

WELLCOME TRUST (UK)

January 2007 - December 2009

Pharmacogenetic and functional analysis of novel GSTP1 polymorphism.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

May 2005 - January 2007

Investigation of the role of Nrf2 in man

WELLCOME TRUST (UK)

October 2011 - May 2015

Mechanism and effect of Chinese antioxidant herbs on phase II drug-metabolizing enzymes.

ROYAL SOCIETY (CHARITABLE)

July 2005 - October 2005

Capacity building award in integrative mammalian biology

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

January 2007 - October 2015

Biomedical Vacation Scholarships

WELLCOME TRUST (UK)

July 2010 - August 2010

University of Liverpool Institutional Discipline Bridging.

MEDICAL RESEARCH COUNCIL (MRC)

October 2003 - October 2006

Analysis of inter-individual variation in the inducibility of the antioxidant response by Nrf2: an important element in the defence against cancer.

NORTH WEST CANCER RESEARCH FUND

May 2005 - April 2006

Hepatocyte Phenotype Project: Phase II proposal

STEM CELLS FOR SAFER MEDICINES LTD (UK)

May 2011 - May 2014